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Abstract
Focal cerebral ischemia following middle cerebral artery occlusion (MCAO) stimulates a robust cytogenic response from the
adult subventricular zone (SVZ) that includes massive proliferation of neural stem/progenitor cells (NSPCs) and cellular
migration into the injury area. To begin to explore beneficial roles of NSPCs in this response, we investigated the ability of
embryonic and postnatal NSPCs to promote neuronal survival under conditions of in vivo and in vitro ischemia. Intracerebral
transplantation of NSPCs attenuated neuronal apoptosis in response to focal ischemia induced by transient MCAO, and
prevented neuronal cell death of cortical neurons in response to oxygen-glucose deprivation (OGD) in culture. NSPC-
mediated neuroprotection was blocked by the pharmacological inhibitors of vascular endothelial growth factor (VEGF),
SU1498 and Flt-1Fc. Embryonic and postnatal NSPCs were both intrinsically resistant to brief OGD exposure, and
constitutively expressed both hypoxia-inducible factor 1a (HIF-1a) transcription factor and its downstream target, VEGF.
Genomic deletion of HIF-1a by Cre-mediated excision of exon 2 in NSPC cultures resulted in .50% reduction of VEGF
production and ablation of NSPC-mediated neuroprotection. These findings indicate that NSPCs promote neuronal survival
under ischemic conditions via HIF-1a-VEGF signaling pathways and support a role for NSPCs in promotion of neuronal
survival following stroke.
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Introduction
Two predominant neurogenic regions persist within the adult
mammalian brain, located within the subgranular zone (SGZ) of
the hippocampal dentate gyrus and the subventricular zone (SVZ)
surrounding the lateral ventricles [1–4]. Neural stem/progenitor
cells (NSPCs) that reside within these brain regions are mitotically
active, self-renewing cells with the potential to differentiate into
neurons, oligodendrocytes, or astrocytes [2,5–7].
Following focal cerebral ischemia, neural stem/progenitor cells
(NSPCs) in the SVZ proliferate and migrate to the lesioned site in
both rodents and humans [8–14]. Migration of NSPCs and their
progeny may be critical for post-ischemic repair, since ablation of
progenitor proliferation leads to increased infarct volume [15] and
the time course of this migratory response occurs concomitant
with partial spontaneous recovery of motor deficits [16,17].
Although hundreds of thousands of cells emigrate from the SVZ
into the injured striatal parenchyma, the number of neuroblasts
that survive long-term represents ,0.2% of striatal neurons lost to
ischemic injury [18]. That such a low number of new neurons
contribute significantly to the reconstruction of striatal circuitry
seems unlikely. Nevertheless, evidence suggests that SVZ deriva-
tives migrating into the injured striatal parenchyma contribute
importantly to the process of endogenous wound healing following
ischemic insult, through processes apart or in addition to neuronal
replacement [19]. Additional mechanisms include stabilization of
nascent vasculature following stroke-induced angiogenesis and/or
prevention of progressive neuronal cell loss via release of
angiogenic and neurotrophic factors.
Vascular endothelial growth factor (VEGF) is the most well-
studied angiogenic factor, but also has been shown to exert direct
neurotrophic signaling and to promote adult neurogenesis
[20–22]. The most potent inducer of VEGF gene expression is
hypoxia [23]. VEGF is transcriptionally regulated by hypoxia
inducible factor-1a (HIF-1a), which translocates to the nucleus
following hypoxia-induced stabilization, dimerizes with HIF-1b
(ARNT), and activates the hypoxia response element (HRE) in the
promoter region of the VEGF gene (for review see [24]). VEGF is
also regulated by HIF-independent mechanisms including other
transcription factors and co-activators [25] (for reviews see
[26,27]), micro-RNAs [28], and inflammatory mediators [29]. In
neurons, VEGF mediates its neurotrophic effects via the receptor
tyrosine kinase, VEGFR-2 (Flk-1/KDR) [21]. Following stroke,
exogenous administration of VEGF has been shown to reduce
infarct size and improve neurological performance [30]. These
effects are thought to be due to both a direct neurotrophic action
of VEGF on neurons and stimulation of angiogenesis for re-
establishment of blood flow following ischemic damage. Trans-
genic mice with VEGF-overexpression also display increased
neurogenesis, decreased infarct volume, and improved motor
function [31].
Neural stem cells have previously been shown to provide
neuroprotection when transplanted into the adult brain in rodent
models of stroke [32–34], raising the possibility that the
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tection of penumbral neurons at risk of delayed cell death. We
have previously demonstrated that embryonic neural stem cells
secrete diffusible VEGF, which underlies their ability to protect
endothelial cells against severe ischemia and promote angiogenesis
in ischemic striatum [35]. In the present study, we investigated
whether embryonic or postnatal NSPCs also provide neuropro-
tection against cerebral ischemia utilizing both in vitro and in vivo
approaches. Here, we demonstrate that both embryonic and
postnatal NSPCs are robustly resistant to oxygen-glucose depri-
vation (OGD), and provide neuroprotection under ischemic
conditions, an effect that is mediated by HIF-1a-regulated release
of diffusible VEGF by primary NSPCs. These studies have
important implications for both the therapeutic use of exogenous
NSPCs in stroke and also suggest a potential neuroprotective role
for endogenous NSPCs in adult brain repair.
Results
NSPCs provide neuroprotection against focal ischemia in
vivo
To determine whether mouse NSPCs are neuroprotective in
our animal model of focal ischemia, we isolated embryonic NSPCs
from transgenic mice that express enhanced green fluorescent
protein (EGFP) under the b-actin promoter. We have previously
demonstrated that these NSPCs fulfill the criteria of multi-
potentiality and self-renewal [35]. EGFP-NSPCs were expanded
in culture and subsequently transplanted into the right dorsal
striatum of adult recipient mice. Control mice received vehicle
injections of phosphate buffered saline only. Seventy-two hours
following transplantation, recipients were subjected to an ipsilat-
eral transient middle cerebral artery occlusion (MCAO) for 30
minutes, followed by three days of reperfusion. As shown in
Figure 1A, MCAO resulted in a robust apoptotic response at three
days as assessed by TUNEL labeling of injured striatum in vehicle
treated mice. EGFP-NSPC recipients displayed .50% fewer
TUNEL+ nuclei compared to vehicle controls (Figure 1B),
particularly in the area immediately surrounding the graft and
extending out to at least 4.5 mm from the graft border
(Figure 1E,F). Conversely, healthy appearing NeuN
+ neuronal
nuclei were numerous near the graft, whereas control mice
displayed widespread loss of NeuN
+ cells (Figure 1C,D). These
data demonstrate robust NSPC-mediated neuroprotection against
focal ischemia in the MCAO model. We previously reported that
NSPC-transplant promotes vascularization and proliferation of
blood vessels within the ischemic striatum [35], suggesting an
effect of NSPCs on the vasculature. Activated neutrophils, as
identified by myeloperoxidase (MPO) staining, were not observed
in either vehicle- or NSPC-injected striatum, suggesting that
NSPC transplantation does not alter the inflammatory response
following stroke (Figure S1). To test whether NSPCs have a direct
effect on neurons during ischemia, we shifted to an in vitro cell
culture system using a well-characterized OGD model [36].
NSPCs provide neuroprotection against OGD and are
intrinsically resistant to in vitro ischemia
We utilized a transwell coculture paradigm to begin to delineate
the mechanisms underlying NSPC-mediated neuroprotection.
NSPCs and cortical neurons were cultured separately as
monocultures or were cocultured in separate compartments of
porous transwells (0.4 mm pore size), which allowed for sharing of
conditioned media but did not allow cell-cell contact between
NSPCs and neurons seeded in the upper vs. lower compartments,
respectively. As shown in Figure 2, cortical cultures contained
MAP-2
+ neurons, with minimal contamination by GFAP
+
astrocytes, and NSPC cultures were uniformly immunopositive
for the stem cell marker, nestin. Neuronal and NSPC cultures were
subjected to control or OGD conditions for 2 hours and assessed
for cell viability 24 hr later using an MTT assay. As shown in
Figure 2B, cortical cultures underwent approximately 40% cell loss
within 24 hr following OGD, as previously described [37], but
only ,12% cell loss when cocultured with NSPCs. Importantly,
NSPC monocultures were robustly resistant to 2 hour OGD and
displayed no significant cell loss at 24 hours (Figure 2C). These
data indicate that NSPCs provide robust neuroprotection of
cortical neurons in culture via diffusible substance(s), and are
themselves resistant to OGD conditions.
Diffusible VEGF is responsible for NSPC-mediated
neuroprotection against OGD
HIF-1a is a key mediator of the adaptive cellular response to
hypoxia and acts through transcriptional and non-transcriptional
pathways to regulate the activities of genes involved in cell survival
and angiogenesis, including VEGF. As shown in Figure 3A, NSPC
monocultures constitutively expressed HIF-1a and displayed a
nearly 3-fold increase in HIF-1a expression measured 24 hr
following a 2 hr exposure to OGD. In contrast, HIF-1a was not
measurable in neuronal monocultures under nonhypoxic condi-
tions or at 24 hr following a 2 hr OGD exposure (not shown). As
shown in Figure 3B, both neuronal and NSPC monocultures
constitutively expressed the HIF-1a target gene, VEGF, and
released VEGF into the culture media. VEGF release was not
statistically different in cortical monocultures following OGD, but
was increased 2.5-fold in NSPC monocultures as measured 24 hr
following 2 hr exposure to OGD. Culture media from NSPCs was
also used to measure the presence of brain-derived neurotrophic
factor (BDNF), however BDNF was undetected in both control
and OGD-exposed NSPC media (data not shown).
To determine whether diffusible VEGF is responsible for
NSPC-mediated neuroprotection, neurons in monoculture or in
transwell coculture with NSPCs were exposed to OGD in the
presence or absence of the VEGFR2 kinase inhibitor, SU1498
(10 mM; Figure 4A) or the VEGF decoy receptor, Flt-1-Fc (1.0 mg/
ml; Figure 4B) added at the onset of OGD and present for 24 hr
thereafter. As demonstrated in Figure 4A, SU1498 had no effect
on neuronal viability under non-ischemic conditions, but com-
pletely inhibited the ability of NSPCs to provide neuroprotection
against OGD in coculture. Prevention of VEGF-VEGFR
interaction at the cell surface with Flt-1-Fc also impaired the
neuroprotection provided by cocultured NSPCs (Figure 4B). Dose-
response analysis for both SU1498 and Flt-1-Fc showed that
neither compound was cytotoxic to neurons in monoculture at the
concentration used in this study (Figure S2). Exposure of neuronal
cultures to NSPC-conditioned media resulted in significant
neuroprotection against OGD, an effect that was also blocked
by SU1498 and Flt-1-Fc inhibition of VEGF signaling (Figure 4C).
Flt-1-Fc was not cytotoxic to NSPCs, and had no effect on the
ability of NSPCs to withstand OGD conditions (Figure S3). These
data indicate that NSPC-mediated neuroprotection is mediated by
diffusible VEGF and dependent on neuronal VEGFR signaling.
Gene deletion of HIF-1a impairs NSPC-mediated
neuroprotection
To determine the extent to which endogenous NSPC HIF-1a
governs VEGF expression and NSPC-mediated neuroprotection,
eNSPCs were isolated from transgenic mice that harbor loxP sites
flanking exon 2 of the HIF-1a gene at both alleles (HIF-1a
fl/fl)
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wt/wt and HIF-1a
fl/fl NSPC cultures were incubated
for 24 hr with adenovirus harboring a bacterial Cre-recombinase
gene sequence to confer Cre expression (Ad-CMV-Cre). As shown
in Figure 5A, transduction of NSPC cultures with Ad-CMV-Cre
resulted in excision of HIF-1a exon 2 in HIF-1a
fl/fl NSPCs (HIF-
1a
D/D), but not in HIF-1a
wt/wt NSPCs, as indicated by PCR
analysis of genomic DNA isolated 24 hr following removal of Ad-
CMV-Cre. HIF-1a transcriptional activity was completely abol-
ished as assessed by the inability of nuclear extract proteins to bind
the hypoxia response element (HRE) in HIF-1a
D/D cells, but not
in HIF-1a
wt/wt cells (Figure 5B). HIF-1a gene deletion in NSPCs
also resulted in a 50% reduction of VEGF release by HIF-1a
D/D
NSPCs compared to HIF-1a
wt/wt NSPCs in response to anoxia
(Figure 5C). HIF-1a gene deletion had no effect on NSPC survival
at 24 hr following 2 hr OGD (96.8 %68.5 % vs. 101.6 %66.7 %,
HIF-1a
wt/wt vs. HIF-1a
D/D, respectively, ns, n=4; Figure S4), but
abrogated the neuroprotective effects of NSPC conditioned media
(Figure 5D). Thus, HIF-1a appears to be necessary for NSPC-
mediated neuroprotection since media from HIF-1a
D/D cultures
failed to protect neurons from OGD-induced death.
Postnatal NSPCs are neuroprotective, resistant to
ischemia and constitutively express stabilized HIF-1a and
VEGF
To determine whether postnatal NSPCs also confer neuropro-
tection and are resistance to in vitro ischemia, we isolated NSPCs
from postnatal day 28 mouse SVZ and expanded the pNSPCs in
Figure 1. NSPCs protect against 30 minute MCAO. (A–D) Coronal histological sections through the ischemic striatum 3 days following MCAO,
stained for TUNEL (A,B) or NeuN (C,D). Mice received intrastriatal injections of exogenous PBS (A,C) or EGFP
+NSPCs (B,D,E) 72 hr prior to MCAO. Inset
in (B) shows 406magnified view of the injection site. (E) Monochrome conversion of image shown in B to demonstrate concentric ring structures
used for Sholl analysis. (F) Quantification of TUNEL+ cells using Sholl analysis performed on fluorescent images. *p,0.05, n=5 mice per group. Scale
bar: A,B = 20 mm; C,D = 10 mm.
doi:10.1371/journal.pone.0009767.g001
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Figure 6 (A and B), pNSPCs constitutively expressed stabilized
HIF-1a and VEGF at levels similar to eNSPCs under non-
ischemic conditions, with robust induction of both proteins in
response to 24 hr anoxia. pNSPCs also displayed resistance to 2 hr
OGD exposure (Figure 6C), and media conditioned by pNSPCs
provided neuroprotection against 2 hr OGD (Figure 6D).
Discussion
In this study, we investigated the neuroprotective effects of
embryonic and postnatal NSPCs under conditions of ischemia,
and the role of HIF-1a-regulated VEGF signaling in this process.
We found that exogenous NSPCs protect neurons against focal
ischemic injury induced by MCAO in vivo, and protect embryonic
cortical neurons against OGD exposure in culture. In contrast to
primary cortical neurons, NSPCs display intrinsic resistance to
brief 2 hr OGD exposure in culture, and constitutively express
stabilized HIF-1a and its downstream target, VEGF. Pharmaco-
logical blockade of VEGF signaling in culture impairs neuropro-
tection, and HIF-1a gene deletion in NSPCs results in both
impaired VEGF production and impaired neuroprotection against
OGD. These observations provide evidence that NSPCs promote
neuronal survival under conditions of ischemia via HIF-1a-
regulated VEGF signaling and suggest that NSPCs may play a
neuroprotective role following stroke.
VEGF is recognized as both a vasculotrophic factor and a
neurotrophic factor. VEGF expression in the brain is downreg-
ulated in early postnatal life after formation of the cerebral
vasculature is complete, but becomes upregulated in adult brain in
response to stroke or mechanical injury [39–41]. Administration of
exogenous VEGF following stroke results in reduced neuronal cell
death, increased angiogenesis and increased vascular permeability
[30,42,43] (reviewed in [42,44,45]). VEGF also exerts a direct
neuroprotective effect against in vitro ischemia, mediated by
neuronal VEGFR2 signaling and downstream activation of the
phosphatidylinositol 3-kinase (PI3 kinase)/Akt pathway in cultured
neurons [46–51]. Our studies suggest that VEGF release by
NSPCs underlies in vitro neuroprotection against ischemia, via
direct activation of neuronal VEGFR2 receptors, since neuropro-
tection was abrogated by the presence of the VEGFR2 kinase
inhibitor, SU1498, and by the presence of the VEGFR decoy
receptor, Flt-1-Fc. In conjunction with our previous report [35],
VEGF could have a dual effect in the graft: improved
revascularization and direct neuroprotection.
VEGF production by both embryonic and adult NSPCs in
culture has previously been reported [35,52–54]. NSPC expression
of VEGF is known to be upregulated in response to hypoxic and
metabolic stress [35,54]. Our present study demonstrates that
cortical cultures also release diffusible VEGF under normoxic
conditions but do not display increased VEGF production at 24 hr
following 2 hr OGD, whereas VEGF release by NSPCs is
increased 2–3 fold within 24 hr post-OGD. Although inhibition
of VEGFR2 signaling blocks NSPC-mediated neuroprotection,
inhibition of VEGFR2 signaling has no impact on the survival of
neurons under normoxic conditions, and has no effect on the
ability of NSPCs to survive ischemic insult. These observations
suggest that increased VEGF production by NSPCs underlies
neuronal protection against in vitro ischemia, but does not mediate
NSPC resistance to ischemic conditions and is not required for
survival of cortical neurons under normoxic conditions.
One of the most potent regulators of VEGF expression is HIF-
1a. HIF-1a is primarily regulated at the post-translational level,
with protein stability dependent upon pO2. In most mammalian
cell types, HIF-1a protein is hydroxylated under normoxic
conditions, binds the von Hippel-Lindau (VHL) protein, and is
rapidly degraded by the 26S proteosome. Under conditions of
hypoxia, HIF-1a is not hydroxylated and rapidly accumulates to
enter the nucleus and dimerize with HIF-1b (ARNT), forming the
Figure 2. NSPCs provide neuroprotection against OGD and are resistant to in vitro ischemia. (A) Diagram of transwell coculture.
Micrograph depicts cortical neurons in lower compartment immunofluorescently labeled for MAP-2 (red) and GFAP (green). NSPCs in upper
compartment are immunofluorescent for nestin (red). Nuclei are labeled with DAPI (blue). (B) Neuronal survival at 24 hrs following 2 hr exposure to
OGD in the absence (left) or presence (right) of NSPCs. (C) Survival of NSPCs grown as monocultures in upper compartment. Data were acquired
using the MTT colorimetric viability assay as described in methods section. *p,0.01, Student’s t-test, n=4 cultures/group.
doi:10.1371/journal.pone.0009767.g002
Figure 3. HIF-1a and VEGF expression in eNSPC cultures under
control vs. OGD conditions. (A) HIF-1a protein levels in cell lysates
from eNSPCs at 24 hrs following a 2 hr exposure to OGD or control
conditions. (B) VEGF within neuronal or NSPC conditioned media
following 2 hr exposure to control or OGD conditions. Media was
conditioned for 24 hrs following exposure to OGD or control
conditions. *p,0.05, Student’s t-test, n=4 cultures/group.
doi:10.1371/journal.pone.0009767.g003
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cis-acting hypoxia response elements (HREs). In most cell types
HIF-1a mRNA is constitutively transcribed and translated, but the
protein only has a half-life of less than 5 minutes under non-
hypoxic conditions (for review, see [24,55]). Our observation that
HIF-1a is constitutively stabilized by cultured NSPCs, even at
21% O2, suggests that NSPCs may also utilize a non-oxygen
dependent mechanism for maintaining HIF-1a stability and that
HIF-1a plays a fundamental role in NSPC homeostasis under both
normoxic and hypoxic conditions. Previous studies have demon-
strated O2-independent stabilization of HIF-1a by heat shock
protein 90 (HSP-90) through binding the PAS domain of HIF-1a
Figure 4. Pharmacological inhibition of VEGF signaling impairs the neuroprotective effects of eNSPCs. (A,B) Neuronal viability 24 hrs
following exposure to 2 hr OGD vs. control conditions in the presence or absence of NSPCs and the VEGFR kinase inhibitor, SU1498 (A) or the VEGF
receptor decoy receptor, Flt-1-Fc (B). (C) Neuronal viability in the presence or absence of NSPC-conditioned media and SU1498 or Flt-1Fc. *p,0.05,
n=4 cultures/group.
doi:10.1371/journal.pone.0009767.g004
NSPC-Mediated Neuroprotection
PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9767Figure 5. Gene deletion of HIF-1a impairs neuroprotective ability of eNSPC. (A) PCR amplification products from genomic DNA isolated
from wild-type and HIF-1a
fl/fl NSPCs exposed to 50 MOI Ad-CMV-Cre for 48 hrs. Excision of exon 2 from HIF-1a gene is indicated by the shorter band
at 250 bp, present after Ad-CMV-Cre exposure of HIF-1a
fl/fl but not wild-type NSPCs. (B) Transcriptional activity of HIF-1a in wild-type vs. HIF-1a
D/D
NSPCs assayed by HRE binding assay. (C) VEGF in 24 hr conditioned media from wild-type vs. HIF-1a
D/D NSPCs. (D) Viability of cortical cultures 24 hr
following 2 hr OGD in the presence or absence of wild-type vs. HIF-1a
D/D NSPCs CM. *p,0.05, n= 4 cultures/group.
doi:10.1371/journal.pone.0009767.g005
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of HIF-1a stability in embryonic mesencephalic NSPCs [57].
While the role of constitutive HIF-1a stabilization in NSPCs is
not completely understood, HIF-1a is recognized as a multifunc-
tional protein that regulates the expression and activity of multiple
genes involved in angiogenesis, glucose metabolism, proliferation
and self-renewal, apoptosis, and migration through both tran-
scriptional and non-transcriptional signaling pathways [58-61].
Others have shown that upregulation of HIF-1a in neural
progenitor cells enhances their ability to survive in vitro and
following transplantation [62], as well as provide neuroprotection
against ischemia [32]. In addition to VEGF, HIF-1a is a potent
inducer of erythropoietin (EPO), which promotes neurogenesis,
NSPC proliferation and neuroprotection following ischemia
[58,63–65]. However, neural-specific EPOR knockdown does
not increase infarct volume following focal cerebral ischemia and
therefore endogenous levels of EPO may not provide neuropro-
tection following stroke [65]. Conversely, antisense blockade of
VEGF in vivo results in an enlargement of infarct volume caused by
transient MCAO [66]. In the present study, we found that HIF-1a
gene deletion results in .50% reduction of VEGF production and
a concomitant impairment of neuroprotective activity in NSPC-
conditioned medium. However, these data also indicate that
VEGF production is at least partially regulated by HIF-1a-
independent mechanisms in NSPCs, since HIF-1a gene deletion
did not completely block VEGF production.
We previously demonstrated that embryonic NSPCs protect
endothelial cells against ischemia-induced damage and stimulate
increased endothelial cell proliferation via HIF-1a-regulated
VEGF signaling mechanisms [35]. Here, we extend those studies
to demonstrate that NSPCs also provide neuroprotection through
similar signaling mechanisms. While neural stem cells were
initially recognized as potential therapeutic agents for stroke and
neurodegenerative disease based on their potential to replace lost
neurons and integrate into host circuitry, our studies support the
possibility that the therapeutic potential of neural stem cells may
Figure 6. Postnatal NSPCs are neuroprotective and resistant to ischemia. (A) HIF-1a protein levels in cell lysates and (B) VEGF concentration
in conditioned medium from pNSPCs at 24 hr following 2 hr exposure to control or OGD conditions. (C) Viability of pNSPCs at 24 hr post-OGD. (D)
Viability of cortical neuronal cultures 24 hr following 2 hr OGD in the presence of neuronal vs. pNSPC conditioned medium. *p,0.05, n=4 cultures/
group.
doi:10.1371/journal.pone.0009767.g006
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repair processes. Following stroke, NSPCs and their progeny
migrate to the lesioned area and inhibition of this migration leads
to an increase in infarct size [15]. Our study reveals that NSPCs
may directly protect against ischemic injury through the release of
diffusible VEGF. Further studies will require NSPC-targeted gene
deletion of VEGF and HIF-1a to delineate the role of endogenous
NSPCs in neuroprotection in vivo, as well as their effects on other
cell types within the neurovascular niche. While in vitro modeling is
crucial to understanding the molecular mechanisms of the
interactions between neurons and NSPCs, in vivo studies will
account for the ischemic microenvironment.
While our studies suggest that NSPCs themselves are neuro-
protective and important for vascular remodeling following stroke,
care must be taken with development of therapeutical strategies.
Direct NSPC transplantation into the post-ischemic environment
may lead to graft overgrowth and tumor formation due to their
pluripotency and ability to self-renew [67]. While VEGF infusion
may look promising, injection of recombinant human VEGF has
been shown to promote blood vessel permeability as well as blood-
brain barrier leakage [43]. Thus, elucidating the mechanisms by
which NSPCs protect the ischemic penumbra following stroke will
provide novel therapeutic strategies for facilitating the contribution
of endogenous NSPCs for brain repair.
Methods
Primary cortical neuronal and neural stem/progenitor
cultures
Ethics Statement: This study was approved by the University
of New Mexico Animal Care and Use Committee and conformed
to the NIH Guidelines for use of animals in research. Timed
pregnant female mice were sacrificed by isoflurane overdose and
the embryos removed by cesarean section. Primary neuronal
cultures were established from cerebral cortices of C57BL/6J
embryos (The Jackson Laboratory, Bar Harbor, ME, USA) at
gestation day 15, using enzymatic dissociation with trypsin as
previously described [37]. For immunocytochemistry, 3.9610
5
dissociated cells were plated on poly-L-lysine-coated coverslips
(0.1 mg/ml; Sigma, St Louis, MO, USA) in 24-well plates. For
biochemical procedures, 1.95610
6 cells were plated on precoated
poly-L-lysine six-well plates (BD Biosciences, San Diego, CA,
USA). The cultures were maintained under serum-free conditions
in neurobasal medium (Invitrogen Corp., Carlsbad, CA, USA),
supplemented with B-27 supplement (2%; Invitrogen Corp.),
glutamine (0.5 mM; Sigma), glutamate (25 mM; Sigma), penicillin
(100 U/ml) and streptomycin (100 mg/ml; Invitrogen Corp.). At
4d a y sin vitro (DIV), half of the medium was removed and
replaced with fresh medium without glutamate, as indicated by
the manufacturer. At 7 DIV, neuronal cultures were used for
experimentation. Embryonic neural stem/progenitor cells
(eNSPC) were established from whole telencephalon of EGFP-
C57BL/6J embryos at gestation day 14 (E14), as described
previously [68]. Postnatal NSPCs (pNSPC) were established from
postnatal day 28 male EGFP-C57BL/6J mice. NSPCs were
plated on pre-coated poly-L-lysine six-well plates (BD Bioscienc-
es). Growth factors were added every other day and cells were
passaged at least twice prior to use. NSPCs used for coculture
were plated on 0.4 mM pore size transwells (BD Biosciences)
coated with poly-L-lysine (0.1 mg/mL; Sigma). The cultures were
maintained under serum-free conditions in neurobasal medium
(Invitrogen Corp.), supplemented with B-27 supplement (2%;
Invitrogen Corp.), glutamine (2.0 mM; Sigma), penicillin
(100 U/ml; Invitrogen Corp.), streptomycin (100 mg/ml; Invitro-
gen Corp.), EGF (10 ng/mL; Invitrogen Corp.), and bFGF
(10 ng/mL; Invitrogen Corp.). All cultures were maintained in a
humidified incubator at 37uCw i t h5 %C O 2. The cultures were
incubated with the following compounds: SU1498 (70 nM–
50 mM; Calbiochem, San Diego, CA, USA), IgG-Fc (5 ng/mL-
1 mg/mL; Jackson ImmunoResearch Laboratories, West Grove,
PA, USA), and Flt-1-Fc (5 ng/mL-1 mg/mL; R&D Systems,
Minneapolis, MN, USA).
Oxygen–glucose deprivation
Oxygen-glucose deprivation (OGD) was performed as previ-
ously described [36,37]. Primary cortical neuronal cultures and/or
NSPCs were placed in an anaerobic chamber (Coy Laboratories,
Grass Lake, MI, USA) containing a gas mixture of 5% CO2,5 %
H2 and 85% N2 (,0.2% O2). Normal culture media was replaced
with deoxygenated, glucose-free Earle’s balanced salt solution, and
the cultures were maintained under glucose-free anaerobic
conditions at 37uC for 2 h. OGD was terminated by returning
the cultures to normoxic conditions and neurobasal medium
supplemented with 2% B-27 supplement, 0.5 mM glutamine,
100 U/ml penicillin and 100 mg/ml streptomycin. As a control,
sister cultures were placed in Earle’s balanced salt solution
containing 25 mM glucose (Sigma) for 2 h at 37uC under
normoxic (21% O2) conditions and then returned under normoxic
conditions to neurobasal medium supplemented with 2% B-27
supplement, 0.5 mM glutamine, 100 U/ml penicillin and 100 mg/
ml streptomycin.
Mild transient middle cerebral artery occlusion (MCAO)
Adult male C57BL/6J mice 20–25 g (The Jackson Laboratory)
were housed under a 12 h light: 12 h dark cycle with food and
water available ad libitum. Mice (20–25 g; n=20) were anesthetized
with 4% isoflurane for induction and maintained on 1.0%
isoflurane. The body temperature was maintained at 37uC with
a heating pad. Mice were subjected to 30 minutes of transient
MCAO as previously described [69]. Briefly, the right common
carotid artery was exposed through a midline incision. The
internal carotid artery was isolated from external carotid artery
which was ligated with 6–0 silk suture. A 2-cm length of 6–0
rounded tip nylon suture was advanced from the common carotid
artery (CCA), through the internal carotid artery up to the level of
the anterior cerebral artery. The suture was inserted 10 to 11 mm
from the bifurcation of CCA to occlude the middle cerebral artery
(MCA). After 30 min of MCAO, the suture was slowly withdrawn
to allow for reperfusion. Reperfusion time was 3 days post-
MCAO. The mice were anesthetized with sodium pentobarbital
(150 mg/kg, Fort Dodge Animal Health, Fort Dodge, IA, USA)
administered intraperitoneally, and were transcardially perfused
first with preperfusing solution (0.01 mg/ml heparin and 1 mg/ml
procaine) and subsequently with 4% paraformaldehyde in 0.1 M
phosphate buffered saline (PBS). The brains were removed, post-
fixed overnight in 4% paraformaldehyde, and cryoprotected with
30% sucrose (w/v) in 0.1 M PBS for 48 hours at 4uC. For
immunohistochemical procedures (described below), the brains
were sectioned at 30 mm using a sliding microtome (AO Scientific
Instruments, Buffalo, NY, USA).
Embryonic NSPC Transplantation
NSPCs isolated from E14 EGFP-expressing transgenic
C57BL/6J mouse embryos were expanded in culture as
d e s c r i b e da b o v ea n dt r a n s p l a n t e di n t o8w e e k - o l dC 5 7 B L / 6 J
mouse striatum. Mice were anaesthetized with 2% isoflurane
inhalation. Stereotaxic injections were performed using Hamil-
ton microsyringe with a 26-gauge blunt needle. Each animal
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concentration 5610
4 cells/ml) of EGFP-NSPCs into the striatum
(from bregma: A +1.0 mm, L +2.0 mm, V 22.6 mm). To
identify fragmentation of DNA characteristic of apoptosis,
TUNEL labeling was performed on paraformaldehyde fixed
tissue from 30 minutes MCAO using NeurotacsTM II kit
(Trevigen, Inc, Gaithersburg, MD, USA), according to the
manufacturer’s protocol. Tissue treated with TACs-nuclease
TM
or without terminal deoxynucleotidyl transferase served as
positive and negative controls, respectively. NIH ImageJ
software was used to quantify TUNEL+ cells from fluorescent
images using Sholl analysis, with concentric rings placed at
increasing distances (635 mm apart) around the perimeter of the
graft.
Immunohistochemistry
Cultured cells were fixed on coverslips with 4% paraformalde-
hyde and incubated in monoclonal mouse anti-Nestin (1:500;
Chemicon, Temecula, CA, USA), polyclonal rabbit anti-MAP-2
(1:500; Chemicon), and/or polyclonal rabbit anti-GFAP (1:500;
Accurate, Westbury, NY, USA). Histological sections (30 mm)
were incubated in monoclonal mouse anti-NeuN (1:1000,
Chemicon) or polyclonal rabbit anti-MPO (1:500, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Immunofluorescence was
visualized using FITC- or Cy3-conjugated secondary antibodies
(1:250; Jackson ImmunoResearch Laboratories). DAPI nuclear
stain was used to identify cell bodies of cultured cells (Invitrogen
Corp.). Immunofluorescence was analyzed using high-resolution
confocal microscopy (Zeiss LSM510, Thornwood, NY, USA) or
conventional fluorescence microscopy.
Immunoassays
S o l u b l eV E G Fo rB D N Fw e r ea s s a y e df r o mc o n d i t i o n e d
media using the Quantikine Mouse Immunoassay for the
appropriate protein (R&D Systems). HIF-1a was measured in
cell lysates using Surveyor
TM IC Human/Mouse Total HIF-1a
Immunoassay (R&D Systems). Transcriptional activity of HIF-
1a was measured in nuclear extract using the TransAM HIF-1
kit (Active Motif, Carlsbad, CA, USA), substituting the
primary antibody for one that recognizes mouse (Novus
Biologicals, Littleton, CO, USA). Nuclear extracts used in this
assay were isolated using the NE-PER Nuclear and Cytoplas-
mic Extraction Reagent Kit (Pierce, Rockford, IL, USA).
Absorbance for all assays was read using a microplate reader
(Dynex Technologies, Chantilly, VA, USA): Quantikine assays
were read at 450 nm with background subtraction of 570 nm;
TransAM assay was read at 450 nm with a background
subtraction of 630 nm.
MTT cell viability assay
Cell viability was assessed using methylthiazolyldiphenyl-
tetrazolium bromide (MTT) dissolved in PBS (0.5 mg/mL;
Sigma). Cultures were incubated with MTT at 37uC for 4 hr.
Formazan crystals were solubilized using 1:1 ethanol:DMSO
solution. Absorbance was measured at 570 nm with a background
subtraction of 630 nm.
HIF-1a gene deletion from NSPCs
NSPCs were isolated from embryonic day 14 transgenic mice
containing loxP-flanked exon 2 of the HIF-1a gene (HIF-1a
fl/fl)
[38] that were crossed to the C57BL/6J background (The Jackson
Laboratory). NSPCs were passaged twice prior to 48 hr treatment
with an adenovirus expressing Cre-recombinase (Ad-CMV-Cre;
Vector Biolabs, Philadelphia, PA, USA) at 50 MOI (multiplicity of
infection). This method recombines the DNA between the two
loxP sites to excise the intervening sequence. Twenty-four hours
after infection, NSPCs were passaged twice more before used in
experiments. To confirm deletion of exon 2 of the HIF-1a gene,
DNA was isolated and efficiency of cre-recombination was
detected with PCR using forward primer 59- TGT TAA ATA
AAA GCT TGG AC -39 and reverse primer 59- GCA GTT AAG
AGC ACT AGT TG -39 [70]. Successful DNA recombination
yields HIF-1a gene-deleted NSPCs (HIF-1a
D/D), as indicated by
the loss of the 1200 bp band amplification product and
appearance of a 250 bp band. Experiments using HIF-1a
D/D
eNSPCs were compared to wild-type C57BL/6J eNSPCs treated
similarly with Ad-CMV-Cre.
Statistical Analysis
Data are expressed as means 6 S.E.M. Significant differences
between means were determined by student’s t-test or analysis of
variance (ANOVA) with Tukey multiple comparisons post hoc
analysis using Prism software (Graphpad Software, San Diego,
CA, USA). P values , 0.05 are considered statistically significant.
Supporting Information
Figure S1 Myeloperoxidase (MPO) staining for activated
neutrophils. (A–D) Myeloperoxidase (MPO) staining of coronal
histological sections through the ischemic striatum 3 days
following MCAO. Mice received intrastriatal injections of
exogenous EGFP+NSPCs (A–C) or PBS (D) 72 hr prior to
MCAO. Scale bar: 10 mm.
Found at: doi:10.1371/journal.pone.0009767.s001 (4.33 MB
TIF)
Figure S2 Dose-response of neurons to SU1498 and Flt-1-Fc.
Neurons were exposed to increasing concentrations of the
VEGFR2 inhibitor SU1498 (A) or the decoy VEGFR1 Flt-1-Fc
(B). SU1498 was cytotoxic at concentrations of 50 and 100 mM,
but not at 10 mM which was the dose used in our experiments (A).
A toxic dose of Flt-1-Fc was not determined (B).
Found at: doi:10.1371/journal.pone.0009767.s002 (0.22 MB TIF)
Figure S3 NSPC response to inhibition of autocrine VEGF.
Embryonic NSPCs were exposed to the VEGFR1 decoy Flt-1-Fc
(1 mg/mL). Flt-1-Fc did not impair the viability of eNSPCs, and
did not impair their ability to survive OGD.
Found at: doi:10.1371/journal.pone.0009767.s003 (0.16 MB TIF)
Figure S4 NSPC viability in response to 2 hr OGD. Deletion of
exon 2 of the HIF-1a gene did not impair eNSPC ability to survive
2 hr OGD, as compared to wild-type eNSPCs.
Found at: doi:10.1371/journal.pone.0009767.s004 (0.14 MB TIF)
Acknowledgments
Confocal images were generated using the University of New Mexico
Cancer Center Fluorescence Microscopy Facility, supported as detailed at
http://hsc.unm.edu/crtc/microscopy/facility.html. The authors thank
Tamara Roitbak, Patrick B. Ventura and Kelsey Thomas for outstanding
technical assistance.
Author Contributions
Conceived and designed the experiments: KMH LL LAC. Performed the
experiments: KMH LL LAC. Analyzed the data: KMH LL LAC.
Contributed reagents/materials/analysis tools: KMH LAC. Wrote the
paper: KMH LAC.
NSPC-Mediated Neuroprotection
PLoS ONE | www.plosone.org 10 March 2010 | Volume 5 | Issue 3 | e9767References
1. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, et al.
(1998) Neurogenesis in the adult human hippocampus. Nat Med 4: 1313–1317.
2. Gage FH (2000) Mammalian neural stem cells. Science 287: 1433–1438.
3. Doetsch F (2003) A niche for adult neural stem cells. Curr Opin Genet Dev 13:
543–550.
4. Alvarez-Buylla A, Lim DA (2004) For the long run: maintaining germinal niches
in the adult brain. Neuron 41: 683–686.
5. McKay R (1997) Stem cells in the central nervous system. Science 276: 66–71.
6. Temple S (2001) The development of neural stem cells. Nature 414: 112–117.
7. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, et al. (2002) A
stem cell molecular signature. Science 298: 601–604.
8. Jin K, Minami M, Lan JQ, Mao XO, Batteur S, et al. (2001) Neurogenesis in
dentate subgranular zone and rostral subventricular zone after focal cerebral
ischemia in the rat. Proc Natl Acad Sci U S A 98: 4710–4715.
9. Jin K, Wang X, Xie L, Mao XO, Zhu W, et al. (2006) Evidence for stroke-
induced neurogenesis in the human brain. Proc Natl Acad Sci U S A 103:
13198–13202.
10. Zhang RL, Zhang ZG, Zhang L, Chopp M (2001) Proliferation and
differentiation of progenitor cells in the cortex and the subventricular zone in
the adult rat after focal cerebral ischemia. Neuroscience 105: 33–41.
11. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O (2002) Neuronal
replacement from endogenous precursors in the adult brain after stroke. Nat
Med 8: 963–970.
12. Parent JM, Vexler ZS, Gong C, Derugin N, Ferriero DM (2002) Rat forebrain
neurogenesis and striatal neuron replacement after focal stroke. Ann Neurol 52:
802–813.
13. Iwai M, Sato K, Kamada H, Omori N, Nagano I, et al. (2003) Temporal profile
of stem cell division, migration, and differentiation from subventricular zone to
olfactory bulb after transient forebrain ischemia in gerbils. J Cereb Blood Flow
Metab 23: 331–341.
14. Yamashita T, Ninomiya M, Hernandez Acosta P, Garcia-Verdugo JM,
Sunabori T, et al. (2006) Subventricular zone-derived neuroblasts migrate and
differentiate into mature neurons in the post-stroke adult striatum. J Neurosci 26:
6627–6636.
15. Maysami S, Lan JQ, Minami M, Simon RP (2008) Proliferating progenitor cells:
a required cellular element for induction of ischemic tolerance in the brain.
J Cereb Blood Flow Metab 28: 1104–1113.
16. Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, et al. (2000)
Transplantation of cultured human neuronal cells for patients with stroke.
Neurology 55: 565–569.
17. Zhang RL, Zhang ZG, Chopp M (2005) Neurogenesis in the adult ischemic
brain: generation, migration, survival, and restorative therapy. Neuroscientist
11: 408–416.
18. Kokaia Z, Thored P, Arvidsson A, Lindvall O (2006) Regulation of stroke-
induced neurogenesis in adult brain--recent scientific progress. Cereb Cortex 16
Suppl 1: i162–167.
19. Burns TC, Verfaillie CM, Low WC (2009) Stem cells for ischemic brain injury: a
critical review. J Comp Neurol 515: 125–144.
20. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, et al. (1989)
Tumor vascular permeability factor stimulates endothelial cell growth and
angiogenesis. J Clin Invest 84: 1470–1478.
21. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, et al. (2002) Vascular endothelial growth
factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad
Sci U S A 99: 11946–11950.
22. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical
progress. Endocr Rev 25: 581–611.
23. Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor
induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:
843–845.
24. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:
721–732.
25. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, et al. (2008) HIF-
independent regulation of VEGF and angiogenesis by the transcriptional
coactivator PGC-1alpha. Nature 451: 1008–1012.
26. Mizukami Y, Kohgo Y, Chung DC (2007) Hypoxia inducible factor-1
independent pathways in tumor angiogenesis. Clin Cancer Res 13: 5670–5674.
27. Birk DM, Barbato J, Mureebe L, Chaer RA (2008) Current insights on the
biology and clinical aspects of VEGF regulation. Vasc Endovascular Surg 42:
517–530.
28. Hua Z, Lv Q, Ye W, Wong CK, Cai G, et al. (2006) MiRNA-directed regulation
of VEGF and other angiogenic factors under hypoxia. PLoS One 1: e116.
29. McColl BK, Stacker SA, Achen MG (2004) Molecular regulation of the VEGF
family -- inducers of angiogenesis and lymphangiogenesis. Apmis 112: 463–480.
30. Sun Y, Jin K, Xie L, Childs J, Mao XO, et al. (2003) VEGF-induced
neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia.
J Clin Invest 111: 1843–1851.
31. Wang Y, Jin K, Mao XO, Xie L, Banwait S, et al. (2007) VEGF-overexpressing
transgenic mice show enhanced post-ischemic neurogenesis and neuromigration.
J Neurosci Res 85: 740–747.
32. Chu K, Jung KH, Kim SJ, Lee ST, Kim J, et al. (2008) Transplantation of
human neural stem cells protect against ischemia in a preventive mode via
hypoxia-inducible factor-1alpha stabilization in the host brain. Brain Res 1207:
182–192.
33. Jin K, Mao X, Xie L, Galvan V, Lai B, et al. (2010) Transplantation of human
neural precursor cells in Matrigel scaffolding improves outcome from focal
cerebral ischemia after delayed postischemic treatment in rats. J Cereb Blood
Flow Metab 30: 534–544.
34. Hayashi J, Takagi Y, Fukuda H, Imazato T, Nishimura M, et al. (2006) Primate
embryonic stem cell-derived neuronal progenitors transplanted into ischemic
brain. J Cereb Blood Flow Metab 26: 906–914.
35. Roitbak T, Li L, Cunningham LA (2008) Neural stem/progenitor cells promote
endothelial cell morphogenesis and protect endothelial cells against ischemia via
HIF-1alpha-regulated VEGF signaling. J Cereb Blood Flow Metab 28:
1530–1542.
36. Plesnila N, Zinkel S, Le DA, Amin-Hanjani S, Wu Y, et al. (2001) BID mediates
neuronal cell death after oxygen/glucose deprivation and focal cerebral
ischemia. Proc Natl Acad Sci U S A 98: 15318–15323.
37. Wetzel M, Li L, Harms KM, Roitbak T, Ventura PB, et al. (2008) Tissue
inhibitor of metalloproteinases-3 facilitates Fas-mediated neuronal cell death
following mild ischemia. Cell Death Differ 15: 143–151.
38. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, et al. (2000) Hypoxia-
inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 60:
4010–4015.
39. Kovacs Z, Ikezaki K, Samoto K, Inamura T, Fukui M (1996) VEGF and flt.
Expression time kinetics in rat brain infarct. Stroke 27: 1865–1873.
40. Krum JM, Rosenstein JM (1998) VEGF mRNA and its receptor flt-1 are
expressed in reactive astrocytes following neural grafting and tumor cell
implantation in the adult CNS. Exp Neurol 154: 57–65.
41. Marti HH, Risau W (1999) Angiogenesis in ischemic disease. Thromb Haemost
82 Suppl 1: 44–52.
42. Greenberg DA, Jin K (2005) From angiogenesis to neuropathology. Nature 438:
954–959.
43. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, et al. (2000) VEGF enhances
angiogenesis and promotes blood-brain barrier leakage in the ischemic brain.
J Clin Invest 106: 829–838.
44. Hansen TM, Moss AJ, Brindle NP (2008) Vascular endothelial growth factor
and angiopoietins in neurovascular regeneration and protection following stroke.
Curr Neurovasc Res 5: 236–245.
45. Carmeliet P, Storkebaum E (2002) Vascular and neuronal effects of VEGF in the
nervous system: implications for neurological disorders. Semin Cell Dev Biol 13:
39–53.
46. Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, et al. (2008) TNF
receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuropro-
tection after ischemic and excitotoxic injury. Proc Natl Acad Sci U S A 105:
6185–6190.
47. Ogunshola OO, Antic A, Donoghue MJ, Fan SY, Kim H, et al. (2002) Paracrine
and autocrine functions of neuronal vascular endothelial growth factor (VEGF)
in the central nervous system. J Biol Chem 277: 11410–11415.
48. Rosenstein JM, Mani N, Khaibullina A, Krum JM (2003) Neurotrophic effects
of vascular endothelial growth factor on organotypic cortical explants and
primary cortical neurons. J Neurosci 23: 11036–11044.
49. Jin KL, Mao XO, Greenberg DA (2000) Vascular endothelial growth factor:
direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A 97:
10242–10247.
50. Kilic E, Kilic U, Wang Y, Bassetti CL, Marti HH, et al. (2006) The
phosphatidylinositol-3 kinase/Akt pathway mediates VEGF’s neuroprotective
activity and induces blood brain barrier permeability after focal cerebral
ischemia. Faseb J 20: 1185–1187.
51. Jin K, Mao XO, Batteur SP, McEachron E, Leahy A, et al. (2001) Caspase-3
and the regulation of hypoxic neuronal death by vascular endothelial growth
factor. Neuroscience 108: 351–358.
52. Teng H, Zhang ZG, Wang L, Zhang RL, Zhang L, et al. (2008) Coupling of
a n g i o g e n e s i sa n dn e u r o g e n e s i si nc u l t u r e de n d o t h e l i a lc e l l sa n dn e u r a l
progenitor cells after stroke. J Cereb Blood Flow Metab 28: 764–771.
53. Wang L, Chopp M, Gregg SR, Zhang RL, Teng H, et al. (2008) Neural
progenitor cells treated with EPO induce angiogenesis through the production of
VEGF. J Cereb Blood Flow Metab 28: 1361–1368.
54. Madhavan L, Ourednik V, Ourednik J (2008) Neural stem/progenitor cells
initiate the formation of cellular networks that provide neuroprotection by
growth factor-modulated antioxidant expression. Stem Cells 26: 254–265.
55. Weidemann A, Johnson RS (2008) Biology of HIF-1alpha. Cell Death Differ 15:
621–627.
56. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, et al. (2002) Hsp90
regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-
degradative pathway. J Biol Chem 277: 29936–29944.
57. Xiong L, Zhao T, Huang X, Liu ZH, Zhao H, et al. (2009) Heat shock protein
90 is involved in regulation of hypoxia-driven proliferation of embryonic neural
stem/progenitor cells. Cell Stress Chaperones 14: 183–192.
58. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, et al. (1999) A
potential role for erythropoietin in focal permanent cerebral ischemia in mice.
J Cereb Blood Flow Metab 19: 643–651.
NSPC-Mediated Neuroprotection
PLoS ONE | www.plosone.org 11 March 2010 | Volume 5 | Issue 3 | e976759. Chen N, Chen X, Huang R, Zeng H, Gong J, et al. (2009) BCL-xL is a target
gene regulated by hypoxia-inducible factor-1{alpha}. J Biol Chem 284:
10004–10012.
60. Bergeron M, Yu AY, Solway KE, Semenza GL, Sharp FR (1999) Induction of
hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia
in rat brain. Eur J Neurosci 11: 4159–4170.
61. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, et al. (2005) Hypoxia
requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9:
617–628.
62. Theus MH, Wei L, Cui L, Francis K, Hu X, et al. (2008) In vitro hypoxic
preconditioning of embryonic stem cells as a strategy of promoting cell survival
and functional benefits after transplantation into the ischemic rat brain. Exp
Neurol 210: 656–670.
63. Chen ZY, Asavaritikrai P, Prchal JT, Noguchi CT (2007) Endogenous
erythropoietin signaling is required for normal neural progenitor cell
proliferation. J Biol Chem 282: 25875–25883.
64. Shingo T, Sorokan ST, Shimazaki T, Weiss S (2001) Erythropoietin regulates
the in vitro and in vivo production of neuronal progenitors by mammalian
forebrain neural stem cells. J Neurosci 21: 9733–9743.
65. Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, et al. (2006) A critical role
of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci
26: 1269–1274.
66. Yang ZJ, Bao WL, Qiu MH, Zhang LM, Lu SD, et al. (2002) Role of vascular
endothelial growth factor in neuronal DNA damage and repair in rat brain
following a transient cerebral ischemia. J Neurosci Res 70: 140–149.
67. Seminatore C, Polentes J, Ellman D, Kozubenko N, Itier V, et al. (2010) The
postischemic environment differentially impacts teratoma or tumor formation
after transplantation of human embryonic stem cell-derived neural progenitors.
Stroke 41: 153–159.
68. Ray J, Peterson DA, Schinstine M, Gage FH (1993) Proliferation, differentiation,
andlong-termcultureofprimaryhippocampalneurons.ProcNatlAcadSciUSA
90: 3602–3606.
69. Kokovay E, Li L, Cunningham LA (2006) Angiogenic recruitment of pericytes
from bone marrow after stroke. J Cereb Blood Flow Metab 26: 545–555.
70. Milosevic J, Maisel M, Wegner F, Leuchtenberger J, Wenger RH, et al. (2007)
Lack of hypoxia-inducible factor-1 alpha impairs midbrain neural precursor cells
involving vascular endothelial growth factor signaling. J Neurosci 27: 412–421.
NSPC-Mediated Neuroprotection
PLoS ONE | www.plosone.org 12 March 2010 | Volume 5 | Issue 3 | e9767